SML1549
Ombrabulin hydrochloride
≥98% (HPLC)
동의어(들):
(2S)-2-Amino-3-hydroxy-N-[2-methoxy-5-[(1Z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl]-propanamide hydrochloride, AC 7700, AVE 8062A, AVE8062, Ombrabulin HCl
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C21H26N2O6 · HCl
CAS Number:
Molecular Weight:
438.90
UNSPSC 코드:
12352200
NACRES:
NA.77
추천 제품
Quality Level
분석
≥98% (HPLC)
양식
powder
저장 조건
desiccated
색상
white to beige
solubility
H2O: 20 mg/mL, clear
저장 온도
2-8°C
SMILES string
Cl.NC(CO)C(=O)Nc1c(ccc(c1)C=Cc2cc(c(c(c2)OC)OC)OC)OC
InChI
1S/C21H26N2O6.ClH/c1-26-17-8-7-13(9-16(17)23-21(25)15(22)12-24)5-6-14-10-18(27-2)20(29-4)19(11-14)28-3;/h5-11,15,24H,12,22H2,1-4H3,(H,23,25);1H
InChI key
UQNRTPFLTRZEIM-UHFFFAOYSA-N
일반 설명
Ombrabulin is a member of the combretastatin A-4 compound class and is a tubulin-depolymerising tumour vascular-disrupting compound.
생화학적/생리학적 작용
Ombrabulin is a synthetic water-soluble combretastatin analog vascular disrupting agent. Ombrabulin is a tubulin polymerization inhibitor. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells.
Ombrabulin is an antitubulin vascular disrupting agent.
Ombrabulin leads to the constriction of the arteries, inhibits cell proliferation and causes detachment of endothelial cells, thereby leading to cytotoxicity. In pre-clinical studies, this compound, along with cisplatin, has shown anti-tumor activity. In tumors, it is responsible for the destruction of the vasculature.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.
Blay JY et al
Lancet Oncology, 16(5), 531-540 (2015)
Phase I safety, pharmacokinetic and pharmacodynamic evaluation of the vascular disrupting agent ombrabulin (AVE8062) in patients with advanced solid tumors.
Sessa C et al
Clinical Cancer Research, 19(17), 4832-4842 (2013)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.